Annual CFI
$9.96 M
-$20.11 M-66.87%
31 December 2023
Summary:
Aptose Biosciences annual cash flow from investing activities is currently $9.96 million, with the most recent change of -$20.11 million (-66.87%) on 31 December 2023. During the last 3 years, it has fallen by -$2.67 million (-21.13%). APTO annual CFI is now -66.87% below its all-time high of $30.07 million, reached on 31 December 2022.APTO Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$0.00
-$2.01 M-100.00%
30 September 2024
Summary:
Aptose Biosciences quarterly cash flow from investing activities is currently $0.00, with the most recent change of -$2.01 million (-100.00%) on 30 September 2024. Over the past year, it has dropped by -$12.95 million (-100.00%). APTO quarterly CFI is now -100.00% below its all-time high of $27.96 million, reached on 31 December 2020.APTO Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$1.96 M
-$12.95 M-86.88%
30 September 2024
Summary:
Aptose Biosciences TTM cash flow from investing activities is currently $1.96 million, with the most recent change of -$12.95 million (-86.88%) on 30 September 2024. Over the past year, it has dropped by -$23.64 million (-92.36%). APTO TTM CFI is now -93.49% below its all-time high of $30.07 million, reached on 31 December 2022.APTO TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APTO Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -66.9% | -100.0% | -92.4% |
| 3 y3 years | -21.1% | +100.0% | -84.7% |
| 5 y5 years | +10000.0% | +100.0% | +121.3% |
APTO Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -66.9% | +128.3% | -100.0% | +100.0% | -93.5% | +105.6% |
| 5 y | 5 years | -66.9% | +128.3% | -100.0% | +100.0% | -93.5% | +105.6% |
| alltime | all time | -66.9% | +128.3% | -100.0% | +100.0% | -93.5% | +105.6% |
Aptose Biosciences Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) | $1.96 M(-86.9%) |
| June 2024 | - | $2.01 M(-200.9%) | $14.91 M(+36.4%) |
| Mar 2024 | - | -$1.99 M(-202.7%) | $10.93 M(+9.7%) |
| Dec 2023 | $9.96 M(-66.9%) | $1.94 M(-85.0%) | $9.96 M(-61.1%) |
| Sept 2023 | - | $12.95 M(-757.2%) | $25.59 M(+238.4%) |
| June 2023 | - | -$1.97 M(-33.4%) | $7.56 M(-61.4%) |
| Mar 2023 | - | -$2.96 M(-116.8%) | $19.60 M(-34.8%) |
| Dec 2022 | $30.07 M(-185.4%) | $17.57 M(-446.1%) | $30.07 M(-500.0%) |
| Sept 2022 | - | -$5.08 M(-150.4%) | -$7.52 M(+186.5%) |
| June 2022 | - | $10.07 M(+34.1%) | -$2.62 M(-65.9%) |
| Mar 2022 | - | $7.50 M(-137.5%) | -$7.69 M(-78.2%) |
| Dec 2021 | -$35.21 M(-378.8%) | -$20.01 M(>+9900.0%) | -$35.21 M(-375.9%) |
| Sept 2021 | - | -$185.00 K(-103.7%) | $12.76 M(+49.0%) |
| June 2021 | - | $5.00 M(-125.0%) | $8.56 M(+69.8%) |
| Mar 2021 | - | -$20.01 M(-171.6%) | $5.04 M(-60.1%) |
| Dec 2020 | $12.63 M(-172.7%) | $27.96 M(-737.9%) | $12.63 M(-153.5%) |
| Sept 2020 | - | -$4.38 M(-396.3%) | -$23.61 M(+16.5%) |
| June 2020 | - | $1.48 M(-111.9%) | -$20.27 M(-31.9%) |
| Mar 2020 | - | -$12.43 M(+50.1%) | -$29.77 M(+71.4%) |
| Dec 2019 | -$17.37 M(<-9900.0%) | -$8.28 M(+694.4%) | -$17.37 M(+89.3%) |
| Sept 2019 | - | -$1.04 M(-87.0%) | -$9.18 M(+12.4%) |
| June 2019 | - | -$8.03 M(>+9900.0%) | -$8.16 M(<-9900.0%) |
| Mar 2019 | - | -$24.00 K(-72.1%) | $12.00 K(0.0%) |
| Dec 2018 | $12.00 K(-101.5%) | -$86.00 K(+207.1%) | $12.00 K(-99.5%) |
| Sept 2018 | - | -$28.00 K(-118.7%) | $2.24 M(-1.8%) |
| June 2018 | - | $150.00 K(-725.0%) | $2.28 M(-370.6%) |
| Mar 2018 | - | -$24.00 K(-101.1%) | -$843.00 K(+3.9%) |
| Dec 2017 | -$811.00 K(-112.5%) | $2.14 M(>+9900.0%) | -$811.00 K(-71.2%) |
| Sept 2017 | - | $12.00 K(-100.4%) | -$2.82 M(-3.6%) |
| June 2017 | - | -$2.97 M(<-9900.0%) | -$2.92 M(-145.1%) |
| Mar 2017 | - | $8000.00(-94.2%) | $6.48 M(+0.1%) |
| Dec 2016 | $6.48 M(+4.9%) | $138.20 K(-247.8%) | $6.48 M(-1.8%) |
| Sept 2016 | - | -$93.50 K(-101.5%) | $6.60 M(+6.8%) |
| June 2016 | - | $6.43 M(>+9900.0%) | $6.18 M(-0.8%) |
| Mar 2016 | - | $2300.00(-99.1%) | $6.23 M(+0.9%) |
| Dec 2015 | $6.17 M(-240.9%) | $256.40 K(-150.1%) | $6.17 M(+4.3%) |
| Sept 2015 | - | -$511.30 K(-107.9%) | $5.92 M(-8.0%) |
| June 2015 | - | $6.48 M(<-9900.0%) | $6.43 M(-163.2%) |
| Mar 2015 | - | -$53.60 K(-99.5%) | -$10.17 M(+0.6%) |
| Dec 2014 | -$4.38 M(-56.6%) | - | - |
| May 2014 | -$10.11 M(<-9900.0%) | -$10.11 M(<-9900.0%) | -$10.11 M(<-9900.0%) |
| Feb 2014 | - | $7200.00(-478.9%) | $9900.00(-10.0%) |
| Nov 2013 | - | -$1900.00(-311.1%) | $11.00 K(-54.2%) |
| Aug 2013 | - | $900.00(-75.7%) | $24.00 K(-17.5%) |
| May 2013 | $29.10 K(>+9900.0%) | $3700.00(-55.4%) | $29.10 K(+14.6%) |
| Feb 2013 | - | $8300.00(-25.2%) | $25.40 K(+92.4%) |
| Nov 2012 | - | $11.10 K(+85.0%) | $13.20 K(+238.5%) |
| Aug 2012 | - | $6000.00(>+9900.0%) | $3900.00(-4000.0%) |
| May 2012 | $0.00(-100.0%) | $0.00(-100.0%) | -$100.00(-97.4%) |
| Feb 2012 | - | -$3900.00(-316.7%) | -$3900.00(-138.6%) |
| Nov 2011 | - | $1800.00(-10.0%) | $10.10 K(-14.4%) |
| Aug 2011 | - | $2000.00(-152.6%) | $11.80 K(-95.2%) |
| May 2011 | $244.70 K | -$3800.00(-137.6%) | $244.60 K(-0.4%) |
| Feb 2011 | - | $10.10 K(+188.6%) | $245.60 K(-48.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2010 | - | $3500.00(-98.5%) | $473.30 K(+0.7%) |
| Aug 2010 | - | $234.80 K(-8485.7%) | $469.80 K(+99.9%) |
| May 2010 | $235.00 K(-95.8%) | -$2800.00(-101.2%) | $235.00 K(-87.8%) |
| Feb 2010 | - | $237.80 K(>+9900.0%) | $1.93 M(-29.4%) |
| Nov 2009 | - | $0.00(0.0%) | $2.73 M(-11.6%) |
| Aug 2009 | - | $0.00(-100.0%) | $3.09 M(-45.1%) |
| May 2009 | $5.62 M(+35.3%) | $1.69 M(+62.2%) | $5.62 M(-4.5%) |
| Feb 2009 | - | $1.04 M(+189.9%) | $5.89 M(-1.0%) |
| Nov 2008 | - | $358.90 K(-85.8%) | $5.95 M(-36.2%) |
| Aug 2008 | - | $2.54 M(+29.7%) | $9.32 M(+124.3%) |
| May 2008 | $4.15 M(-182.5%) | $1.95 M(+77.4%) | $4.15 M(+142.1%) |
| Feb 2008 | - | $1.10 M(-70.4%) | $1.72 M(-223.3%) |
| Nov 2007 | - | $3.73 M(-241.7%) | -$1.39 M(-83.3%) |
| Aug 2007 | - | -$2.63 M(+443.8%) | -$8.35 M(+65.8%) |
| May 2007 | -$5.04 M(-142.7%) | -$483.80 K(-75.9%) | -$5.04 M(-31.0%) |
| Feb 2007 | - | -$2.01 M(-37.9%) | -$7.30 M(+106.8%) |
| Nov 2006 | - | -$3.23 M(-573.2%) | -$3.53 M(-163.0%) |
| Aug 2006 | - | $682.50 K(-124.9%) | $5.60 M(-52.5%) |
| May 2006 | $11.79 M(+132.0%) | -$2.74 M(-255.7%) | $11.79 M(-17.1%) |
| Feb 2006 | - | $1.76 M(-70.1%) | $14.22 M(+68.1%) |
| Nov 2005 | - | $5.90 M(-14.1%) | $8.46 M(+208.1%) |
| Aug 2005 | - | $6.87 M(-2320.9%) | $2.75 M(-45.9%) |
| May 2005 | $5.08 M(-480.0%) | -$309.30 K(-92.3%) | $5.08 M(-56.5%) |
| Feb 2005 | - | -$4.00 M(-2231.8%) | $11.68 M(-41.4%) |
| Nov 2004 | - | $187.70 K(-98.0%) | $19.95 M(+73.5%) |
| Aug 2004 | - | $9.20 M(+46.3%) | $11.50 M(-959.7%) |
| May 2004 | -$1.34 M(-116.4%) | $6.29 M(+47.6%) | -$1.34 M(-80.5%) |
| Feb 2004 | - | $4.26 M(-151.6%) | -$6.85 M(-20.0%) |
| Nov 2003 | - | -$8.26 M(+127.8%) | -$8.56 M(-445.6%) |
| Aug 2003 | - | -$3.63 M(-564.5%) | $2.48 M(-69.6%) |
| May 2003 | $8.14 M(+39.8%) | $781.20 K(-69.3%) | $8.14 M(+9.9%) |
| Feb 2003 | - | $2.55 M(-8.2%) | $7.41 M(-37.6%) |
| Nov 2002 | - | $2.78 M(+36.3%) | $11.89 M(+280.3%) |
| Aug 2002 | - | $2.04 M(+4066.9%) | $3.13 M(-46.3%) |
| May 2002 | $5.82 M(-122.1%) | $48.90 K(-99.3%) | $5.82 M(-465.6%) |
| Feb 2002 | - | $7.02 M(-217.4%) | -$1.59 M(-259.3%) |
| Nov 2001 | - | -$5.98 M(-226.3%) | $1.00 M(-225.5%) |
| Aug 2001 | - | $4.74 M(-164.3%) | -$796.60 K(-97.0%) |
| May 2001 | -$26.37 M(+547.7%) | -$7.37 M(-176.6%) | -$26.37 M(+239.1%) |
| Feb 2001 | - | $9.62 M(-223.6%) | -$7.78 M(-53.3%) |
| Nov 2000 | - | -$7.78 M(-62.7%) | -$16.66 M(-32.9%) |
| Aug 2000 | - | -$20.84 M(-285.6%) | -$24.84 M(+510.1%) |
| May 2000 | -$4.07 M(-23.0%) | $11.23 M(+1443.1%) | -$4.07 M(-81.1%) |
| Feb 2000 | - | $727.60 K(-104.6%) | -$21.58 M(-2.9%) |
| Nov 1999 | - | -$15.96 M(>+9900.0%) | -$22.23 M(+256.1%) |
| Aug 1999 | - | -$66.90 K(-98.9%) | -$6.24 M(+18.0%) |
| May 1999 | -$5.29 M(-297.6%) | -$6.28 M(-7680.6%) | -$5.29 M(-667.8%) |
| Feb 1999 | - | $82.90 K(+223.8%) | $931.60 K(-59.9%) |
| Nov 1998 | - | $25.60 K(-97.1%) | $2.32 M(+21.8%) |
| Aug 1998 | - | $885.90 K(-1510.7%) | $1.91 M(-28.8%) |
| May 1998 | $2.68 M(-147.3%) | -$62.80 K(-104.3%) | $2.68 M(-2.3%) |
| Feb 1998 | - | $1.48 M(-477.4%) | $2.74 M(+116.6%) |
| Nov 1997 | - | -$390.90 K(-123.6%) | $1.26 M(-23.6%) |
| Aug 1997 | - | $1.66 M | $1.66 M |
| May 1997 | -$5.66 M | - | - |
FAQ
- What is Aptose Biosciences annual cash flow from investing activities?
- What is the all time high annual CFI for Aptose Biosciences?
- What is Aptose Biosciences annual CFI year-on-year change?
- What is Aptose Biosciences quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Aptose Biosciences?
- What is Aptose Biosciences quarterly CFI year-on-year change?
- What is Aptose Biosciences TTM cash flow from investing activities?
- What is the all time high TTM CFI for Aptose Biosciences?
- What is Aptose Biosciences TTM CFI year-on-year change?
What is Aptose Biosciences annual cash flow from investing activities?
The current annual CFI of APTO is $9.96 M
What is the all time high annual CFI for Aptose Biosciences?
Aptose Biosciences all-time high annual cash flow from investing activities is $30.07 M
What is Aptose Biosciences annual CFI year-on-year change?
Over the past year, APTO annual cash flow from investing activities has changed by -$20.11 M (-66.87%)
What is Aptose Biosciences quarterly cash flow from investing activities?
The current quarterly CFI of APTO is $0.00
What is the all time high quarterly CFI for Aptose Biosciences?
Aptose Biosciences all-time high quarterly cash flow from investing activities is $27.96 M
What is Aptose Biosciences quarterly CFI year-on-year change?
Over the past year, APTO quarterly cash flow from investing activities has changed by -$12.95 M (-100.00%)
What is Aptose Biosciences TTM cash flow from investing activities?
The current TTM CFI of APTO is $1.96 M
What is the all time high TTM CFI for Aptose Biosciences?
Aptose Biosciences all-time high TTM cash flow from investing activities is $30.07 M
What is Aptose Biosciences TTM CFI year-on-year change?
Over the past year, APTO TTM cash flow from investing activities has changed by -$23.64 M (-92.36%)